Renacet

Quick links to important sections

Renacet

Method of action: Mineral, Mineral Supplements

Treatment option: Hyperphosphatemia

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Renacet

What is Renacet? — Quick Facts and Identity

Property Description
Active ingredient Calcium Acetate (Ca(CH3COO)2)
Form Solid oral preparation (Tablet/Capsule)
Pharmacological class Phosphate Binder
Common use Management of hyperphosphatemia
Origin Synthetic compound (Mineral-based)

What Type of Medicine is Renacet and its Primary Role?

Renacet is a prescription medication classified as a Phosphate Binder, a specialized agent used to control elevated phosphate levels in the blood. Its primary therapeutic purpose is the management of hyperphosphatemia, a condition prevalent in patients with advanced Chronic Kidney Disease (CKD) and those undergoing dialysis. It is indicated for the treatment of this condition.

This classification signifies that the drug's therapeutic action is highly specific, designed to regulate a critical mineral imbalance. As a Phosphate Binder, Renacet helps reduce the physiological burden of excess phosphate, contributing to the overall stability of the patient's mineral profile. It is an established option for managing this condition within renal medicine.


Composition, Origin, and Dosage Form

The active component in Renacet is Calcium Acetate (Ca(CH3COO)2), which is the calcium salt of acetic acid. This agent is a synthetic compound derived from mineral components and is formulated as a solid oral preparation, available for ingestion as a tablet or capsule.

As a single-active-ingredient product, its efficacy relies on the chemical properties of the Calcium Acetate. Calcium-containing phosphate binders are used to reduce serum phosphate concentrations in adults with End-Stage Renal Disease (ESRD). The specific formulation of Calcium Acetate offers a differentiating factor: it provides the reactive acetate salt, which is utilized for its solubility and rapid binding capability within the gastrointestinal tract compared to less soluble calcium salts.


How Does Renacet Act on Dietary Phosphate?

Renacet functions via a direct, localized chemical process within the digestive system. The medication releases calcium ions that immediately bond with the dietary phosphate from a consumed meal. This chemical process prevents the phosphate from being absorbed into the bloodstream by creating an inert, unabsorbable substance known as calcium phosphate.

The complex is then passed through the intestines and eliminated via stool. This interception mechanism is the key to the drug's overall therapeutic effect: maintaining balanced phosphate levels essential for patients whose normal kidney filtration process is compromised, such as during a typical course of treatment for mineral bone disorder associated with CKD.

Regulatory References

  1. hyperphosphatemia
  2. Chronic Kidney Disease (CKD)

What side effects are possible with Renacet?

Possible Side Effects and Safety Information

The official safety profile of Renacet (Calcium Acetate) is based on the risk of elevated calcium levels, which is the key safety consideration documented in regulatory labeling.

Frequency-Classified Adverse Reactions

The most frequently reported adverse reactions are categorized by their incidence in official prescribing information:

  • Very Common (ge 1/10): Hypercalcemia (elevated serum calcium), Nausea, and Diarrhea.
  • Common (1/100 to <1/10): Vomiting and Constipation.
  • Uncommon (0.1% to <1%): Soft tissue calcification.

These effects primarily involve Metabolism and Nutrition Disorders (Hypercalcemia) and Gastrointestinal Disorders.

Serious Adverse Reactions and Safety Constraints

The regulatory labels identify clinically significant risks, primarily associated with severe calcium imbalance. Serious adverse reactions documented include manifestations of Severe Hypercalcemia (such as confusion or stupor) and the risk of Vascular and Soft-Tissue Calcification associated with chronic, unmanaged hypercalcemia.

Specific regulatory constraints state that Renacet is contraindicated in patients with pre-existing Hypercalcemia or Hypophosphatemia. The labeling also cautions against the concurrent use of other calcium supplements.

Safety Patterns and Special Populations

Official documentation notes that the risk of progressive hypercalcemia is highest early in treatment or during dose adjustments, requiring strict monitoring. For special populations, specific safety considerations are documented for ESRD patients due to their propensity for hypercalcemia, and for pregnant patients due to risks related to maternal hypercalcemia.

Overdose and Emergency Response

Overdose and When to Seek Help

The official prescribing information for Renacet (Calcium Acetate) identifies the primary consequence of an overdose as hypercalcemia—an abnormally high level of calcium in the blood. Overdose presentations are directly linked to the severity of this condition.

Documented Overdose Manifestations

Symptoms officially documented in regulatory sources range from gastrointestinal discomfort to severe neurological effects:

  • Mild Symptoms: Anorexia (loss of appetite), nausea, vomiting, and constipation.
  • Severe Symptoms: Progressive hypercalcemia can lead to changes in mental status, including confusion, stupor, and coma.

Required Emergency Actions

The regulatory label mandates specific actions based on the severity of the overdose:

  • Immediate Medical Attention: Should be sought if symptoms of severe hypercalcemia (e.g., stupor, coma) are present, as the situation may require emergency measures.
  • Supportive Management: For severe cases, management may include acute hemodialysis and discontinuation of Renacet therapy. No specific antidote is documented.

Population-Specific Considerations

The official label notes specific risks for certain patients:

  • Cardiac Risks: Hypercalcemia from overdose may worsen existing digitalis toxicity and potentially precipitate cardiac arrhythmias in patients taking cardiac glycosides (like digitalis).
  • Monitoring: Serum calcium levels must be monitored in hypercalcemic situations.

Therapeutic Uses of Renacet

Renacet: Uses and Therapeutic Areas

Quick Facts

  • Primary Use: Helps reduce high concentrations of phosphate in the blood (hyperphosphatemia).
  • Patient Population: Indicated for individuals with end-stage kidney disease (ESRD) or chronic kidney disease (CKD) who are on dialysis.
  • Therapeutic Goal: Works as a supportive measure in a comprehensive treatment plan to manage serum phosphorus levels.

Renacet is a prescribed medication intended for use in the management of hyperphosphatemia, a condition characterized by elevated levels of phosphate in the bloodstream. This condition is commonly observed in patients undergoing long-term dialysis as a result of chronic or end-stage kidney disease.

The therapeutic purpose of Renacet is to help reduce the amount of phosphate absorbed by the body. By helping to maintain serum phosphate levels within a specified range, the medication serves as an important component of the overall treatment strategy for renal patients. Healthcare professionals may recommend this treatment to address the metabolic imbalances associated with reduced kidney function.

Renacet is indicated for use alongside dietary modifications and the dialysis regimen to achieve the desired effect.

Eligibility and Restrictions for Use

Renacet, which contains calcium acetate, is a phosphate binder primarily indicated for the control of hyperphosphatemia (high phosphate levels) in adult patients with end-stage kidney disease who are undergoing dialysis treatment. Its use aims to prevent complications such as ectopic calcification and secondary hyperparathyroidism.

Who Should Not Use Renacet

Renacet is contraindicated and should not be used by individuals with certain pre-existing conditions, as its use could lead to serious health risks. These conditions include:

  • Hypercalcemia: Increased concentrations of calcium in the blood.
  • Hypophosphatemia: Reduced phosphate concentrations in the blood.
  • Allergy or Hypersensitivity: Known allergy to calcium acetate or any other component (excipients) of the tablet.

Patients with conditions like severe hypercalciuria (increased calcium excretion in urine) associated with kidney stones or decalcifying tumors should also typically avoid Renacet. Additionally, those taking other calcium-containing supplements or antacids should only use Renacet under strict medical supervision due to the increased risk of dangerously high calcium levels. Safety and efficacy in the pediatric population have not been fully established, and its use in children must be determined by a specialist physician.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation defines the interaction profile of Renacet (Calcium Acetate) through two primary mechanisms: the reduction of oral drug exposure and the risk of pharmacodynamic hypercalcemia.


Drug–Drug Interactions Affecting Absorption

Renacet’s active component binds to certain orally administered drugs in the gastrointestinal tract, a cation binding effect that reduces their overall absorption and plasma exposure. This pharmacokinetic interaction necessitates timing separation for several agents. Specific medicines and classes listed in official documents include:

  • Antibiotics: Specifically tetracyclines (e.g., Doxycycline) and fluoroquinolones (e.g., Ciprofloxacin).
  • Thyroid Replacement Therapy: Levothyroxine.
  • Bisphosphonates.

For these and other oral medications where reduced bioavailability is clinically significant, regulatory rules specify that the co-administered drug should be taken either one hour before or three hours after Renacet.


Pharmacodynamic and Supplemental Restrictions

Co-administration with certain products carries a hypercalcemia risk due to additive effects on the body's calcium levels. Official restrictions include:

  • Avoidance: Concurrent use with oral calcium supplements and calcium-based antacids must be avoided.
  • Caution: The combination with thiazide diuretics may increase the risk of hypercalcemia. If hypercalcemia occurs, it may aggravate the effects of cardiac glycosides (e.g., Digoxin).

Mechanism of Action

Peripheral Phosphate Sequestration and Binding

Renacet's mechanism of action is confined to the gastrointestinal (GI) tract lumen, classifying it as a peripheral binder. Upon oral administration, the compound releases free calcium ions (Ca^2+), which serve as the active binding moiety. These ions immediately interact with dietary phosphate (H2PO4^- and HPO4^2-), forming a complex via ionic complexation. This process results in the creation of insoluble calcium phosphate (Ca3(PO4)2) within the digestive system.


Modulating the Absorption-Excretion Axis

The insoluble calcium phosphate complex is not substrate for absorption across the intestinal wall. Consequently, the drug fundamentally alters the absorption-excretion axis for phosphate by preventing its systemic entry. The complex is subsequently excreted in the feces, resulting in a net reduction in the amount of phosphate available for circulation. This mechanistic cascade directly contributes to a decrease in serum phosphate concentration.


Influencing Systemic Mineral Homeostasis

As a physiological consequence, the reduction in systemic phosphate levels indirectly modulates the complex feedback mechanisms regulating the calcium-phosphate homeostatic axis. This influence on mineral balance affects downstream physiological responses, including the regulation of parathyroid hormone (PTH) activity, by adjusting the concentrations of circulating phosphate and calcium.

Dosage and Administration Information

How to Use Renacet: Official Administration Guidelines

The administration of Renacet (Calcium Acetate) is highly dependent on food intake, as its primary action is a localized chemical process within the digestive system. The route of administration is strictly oral, and the medication is available in solid forms, such as tablets or capsules, with common strengths including 667 mg.


Dosing and Procedural Structure

The medication is to be taken multiple times daily and must be ingested during or immediately after a meal or snack to bind with dietary phosphate. This essential timing is necessary for the drug to function as intended. Tablets or capsules should be swallowed whole with liquid and must not be chewed or crushed.

Standard Adult Dosing begins with an initial regimen, such as two 667 mg tablets/capsules with each meal. The dose is not fixed; it is subsequently titrated gradually every two to three weeks until the desired level of serum phosphorus is achieved. The maintenance dose may require three to four tablets/capsules with each meal for some patients.

Population and Missed Dose Rules

Category Official Instruction
Pediatric Use Safety and effectiveness have not been established in patients under 18 years of age.
Missed Dose Rule If a dose is missed, the patient should not take a double dose. Treatment should continue as originally scheduled.

This protocol establishes Renacet's use as a continuous, meal-synchronized treatment, requiring highly individualized and flexible dosing.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Renacet

Evidence for use in Major Depressive Disorder (MDD)

This section summarizes the types of research available, primarily Randomized Controlled Trials (RCTs) and meta-analyses, that examined measurements on scales related to depressive symptoms in adults.

Research focused on individuals diagnosed with MDD, a condition marked by functional limitations. The studies monitored individuals over defined time intervals, primarily short-term (six to eight weeks). Researchers examined outcomes related to systemic imbalance using standardized tools to measure symptom intensity and patient-reported outcomes. Findings describe patterns observed in the studies related to measured changes in the observed populations, including measurements reported on standardized scales used to assess symptom severity, as well as outcomes related to sleep and appetite.

Evidence for use in Generalized Anxiety Disorder (GAD)

This section outlines the structure of the existing research for this condition, which mainly consists of retrospective analyses and small open-label studies, and describes the symptom outcomes that were measured.

For GAD, Renacet was studied for outcomes related to systemic imbalance, specifically anxiety symptom scores. Research has largely consisted of observational settings. Studies reported measurements of symptom scores in the observed populations over short intervals. The evidence is limited and heterogeneous for this condition, with a lack of dedicated comparative trials and modest sample sizes.

What is Still Uncertain About Renacet

A primary limitation is that long-term outcomes are not fully established, as most trials focused on short or intermediate follow-up durations. This means there is limited information on measurements that occur over many years of research. For several conditions that have been studied, the evidence is limited, and evidence quality varies across studies. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. The effects of mirtazapine on sleep in patients with major depressive disorder (Review)

Frequently Asked Questions (FAQ)

Common questions about Renacet (FAQ)


Q: Does Renacet interact with common pain relievers like ibuprofen?

Regulatory documents state that Renacet can reduce the absorption of certain oral medications, which may necessitate time separation for proper absorption. However, specific interactions with common over-the-counter pain relievers such as ibuprofen are not explicitly listed in the main interaction summaries from official product information.


Q: Is Renacet safe to use long-term?

Renacet is prescribed for hyperphosphatemia, a chronic condition, and is typically used for continuous management. Official documents indicate, however, that the full long-term effect of the medication on the progression of serious health risks, such as the hardening of soft tissues or blood vessels (calcification), has not been determined in research.


Q: Do I need a special diet while using Renacet?

The official product information notes that diet is a factor in treatment, as the medication is designed to work by binding with dietary phosphate from the food being consumed. The medication's function relies entirely on coordination with meals.


Q: How does Renacet affect [specific body system, e.g., blood pressure]?

The active ingredient in Renacet, which is calcium, can indirectly influence the heart. The official warnings note that if calcium levels become too high, it may worsen the risk of irregular heart rhythm in patients taking heart medications known as cardiac glycosides (like Digitalis). The drug is not typically listed as having a direct effect on blood pressure.


Q: Does Renacet need to be taken at a specific time of day?

According to official administration instructions, the timing of Renacet is linked to food, not a specific hour. The medication is required to be taken during or immediately after a meal or snack, as its function is dependent on binding with dietary phosphate in the food.


Q: Does Renacet require regular monitoring (like blood tests)?

Official safety information emphasizes that strict monitoring of serum calcium levels is a required part of treatment. The need for close observation is especially noted during the initial phase and during dose adjustments.


Q: Are allergic reactions to Renacet common?

Official product information lists hypersensitivity (allergic reaction) as a condition that prevents use (contraindication). However, the frequency of allergic reactions is not consistently classified (e.g., as common or very common) in the main adverse event tables in regulatory summaries.


Q: Can I take other supplements with Renacet?

Official warnings state that concurrent use of oral calcium supplements and calcium-based nonprescription antacids should be avoided. The drug’s interaction profile requires evaluation to determine if other supplements contain calcium or other ingredients known to interact with the medication.


Q: Can Renacet cause weight changes?

Weight loss has been mentioned in official postmarketing reports following the medication's release to the public. However, weight changes are not consistently listed among the common or very common side effects found in the main adverse reaction tables.


Q: Is there a generic version of Renacet available?

The medication is available as the brand name product, Renacet, and as the generic product, which is named Calcium Acetate. Generic versions of this medication are widely available in various markets.


Q: Is Renacet considered an opioid?

Official drug information sources classify Renacet as a phosphate binder. It is explicitly listed as a non-controlled medication, meaning it is not a substance that carries the classification of an opioid.


Q: Can Renacet be used by women who are breastfeeding?

Excretion of the active component, calcium acetate, into human milk has been noted. Official documentation requires appropriate monitoring of the mother’s serum calcium levels (calcium in the blood).


Q: What is the difference between the brand name and the generic form of Renacet?

The generic form of the drug contains the same active ingredient, calcium acetate, as the brand name product. By regulatory standard, the generic version is held to the same quality and effectiveness requirements as the brand name version.


Q: Can Renacet cause dependency or addiction?

Official government drug classifications state that Renacet is a non-controlled medication. Therefore, it is not listed as carrying a known risk of physical dependence or addiction.


Q: Does Renacet make you drowsy or tired?

Official documents note that symptoms like dizziness and weakness have been reported after the drug was released. Furthermore, unusual tiredness can be a symptom of hypercalcemia (too much calcium), which is a commonly reported adverse reaction of the medication.


Q: Can older adults use Renacet safely?

Studies did not include enough subjects aged 65 and older to determine if they respond differently than younger patients. Official guidance states that treatment should be cautious for elderly patients, given the potential for different responses compared to younger patients.


Q: Are headaches a common side effect of Renacet?

Headache is not typically listed as a common or very common adverse reaction in official product safety tables. However, a headache has been reported as a symptom, particularly when associated with severe hypercalcemia.


Q: Is Renacet a blood thinner?

Renacet is classified by regulatory agencies as a phosphate binder. It is not a part of the pharmacological class of medications that are known as blood thinners or anticoagulants.


Q: Is Renacet approved in countries outside of the US?

The active ingredient, calcium acetate, is approved and available under various brand names, including Renacet, in countries outside of the US. For instance, it is available in the UK/Europe under the same regulatory classification.


Q: Does Renacet have a risk of causing liver problems?

The most common adverse reactions listed in official safety documents primarily involve the digestive system and mineral balance (metabolism). Issues with the liver (hepatic problems) are generally not listed as commonly reported side effects.


Q: What does the box warning (Black Box) for Renacet mean?

According to the official prescribing information from the U.S. FDA, Renacet (Calcium Acetate) does not carry a Black Box Warning. The most serious warnings in the labeling relate to the risk of severe hypercalcemia (high calcium levels).

How should Renacet be stored and disposed of?

Storage Conditions and Handling

Renacet (calcium acetate) must be stored at Controlled Room Temperature, typically 20 to 25 C (68 to 77 F). The medication must be kept away from excess heat and moisture to maintain its stability and should not be stored in humid areas like a bathroom.

For product protection, it is required to keep the medication in the original container and ensure the container remains tightly closed when not in use. Additionally, the tablets or capsules must be swallowed whole and not chewed to preserve the intended release profile. The approved shelf-life for the product is generally three years, provided it is stored according to these guidelines.

Child Safety and Disposal

It is a mandatory safety instruction to keep this and all drugs out of reach of children and to secure it in a location that is out of their sight. For disposal, unused or expired medication must be handled according to local regulations for pharmaceutical waste, and it should not be discarded into sewers or waterways.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Renacet found in:

A-Z Index: